Patients were randomised ( 1:1 ) via a centralised , interactive voice-response system to receive 8 mg/kg intravenous ramucirumab plus FOLFIRI or matching placebo plus FOLFIRI every 2 weeks until disease progression , unacceptable toxic effects , or death .